Download PDF
Semin Reprod Med 2010; 28(1): 081-090
DOI: 10.1055/s-0029-1242998
© Thieme Medical Publishers

Role of Progesterone in Endometrial Cancer

J. Julie Kim1 , Eloise Chapman-Davis1 , 2
  • 1Department Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
  • 2Division of Gynecologic Oncology, Northwestern University, Chicago, Illinois
Further Information

Publication History

Publication Date:
26 January 2010 (online)

    Permissions and Reprints

ABSTRACT

Progesterone is a key hormone in the endometrium that opposes estrogen-driven growth. Insufficient progesterone will result in unopposed estrogen action that could lead to the development of endometrial hyperplasia and adenocarcinoma. Although these endometrial neoplasias can regress in response to progestin treatment, this does not occur in all instances. To understand this resistance to progesterone and to improve on existing hormonal therapies, it is imperative that the molecular mechanisms of progesterone action through its receptor be deciphered in endometrial cancer. This review highlights what is known thus far regarding the efficacy of progestin therapy in the clinic and the role of progesterone in endometrial cancer cell behavior and gene regulation.

KEYWORDS

Progesterone receptor - endometrial cancer - uterus - progesterone

REFERENCES

  • 1 Kurita T, Nakamura H. Embryology and Anatomy of the Uterus. 2nd ed. Newark, NJ; Harwood Academic 2007
    PubMedGoogle Scholar
  • 2 Clarke C L, Sutherland R L. Progestin regulation of cellular proliferation.  Endocr Rev. 1990;  11(2) 266-301
    CrossrefPubMedGoogle Scholar
  • 3 Dockery P, Li T C, Rogers A W, Cooke I D, Lenton E A. The ultrastructure of the glandular epithelium in the timed endometrial biopsy.  Hum Reprod. 1988;  3(7) 826-834
    PubMedGoogle Scholar
  • 4 Wynn R M. Ultrastructural development of the human decidua.  Am J Obstet Gynecol. 1974;  118(5) 652-670
    PubMedGoogle Scholar
  • 5 Gellersen B, Brosens J. Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair.  J Endocrinol. 2003;  178(3) 357-372
    CrossrefPubMedGoogle Scholar
  • 6 Mulac-Jericevic B, Mullinax R A, DeMayo F J, Lydon J P, Conneely O M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform.  Science. 2000;  289(5485) 1751-1754
    CrossrefPubMedGoogle Scholar
  • 7 Gronemeyer H, Meyer M E, Bocquel M T, Kastner P, Turcotte B, Chambon P. Progestin receptors: isoforms and antihormone action.  J Steroid Biochem Mol Biol. 1991;  40(1-3) 271-278
    CrossrefPubMedGoogle Scholar
  • 8 Kastner P, Krust A, Turcotte B et al.. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B.  EMBO J. 1990;  9(5) 1603-1614
    PubMedGoogle Scholar
  • 9 Lessey B A, Alexander P S, Horwitz K B. The subunit structure of human breast cancer progesterone receptors: characterization by chromatography and photoaffinity labeling.  Endocrinology. 1983;  112(4) 1267-1274
    CrossrefPubMedGoogle Scholar
  • 10 Chi T, Lieberman P, Ellwood K, Carey M. A general mechanism for transcriptional synergy by eukaryotic activators.  Nature. 1995;  377(6546) 254-257
    PubMedGoogle Scholar
  • 11 Giangrande P H, Kimbrel E A, Edwards D P, McDonnell D P. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.  Mol Cell Biol. 2000;  20(9) 3102-3115
    CrossrefPubMedGoogle Scholar
  • 12 McDonnell D P, Shahbaz M M, Vegeto E, Goldman M E. The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity.  J Steroid Biochem Mol Biol. 1994;  48(5-6) 425-432
    CrossrefPubMedGoogle Scholar
  • 13 Tetel M J, Giangrande P H, Leonhardt S A, McDonnell D P, Edwards D P. Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo.  Mol Endocrinol. 1999;  13(6) 910-924
    CrossrefPubMedGoogle Scholar
  • 14 Tung L, Abdel-Hafiz H, Shen T et al.. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B.  Mol Endocrinol. 2006;  20(11) 2656-2670
    CrossrefPubMedGoogle Scholar
  • 15 Tung L, Mohamed M K, Hoeffler J P, Takimoto G S, Horwitz K B. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors.  Mol Endocrinol. 1993;  7(10) 1256-1265
    CrossrefPubMedGoogle Scholar
  • 16 Vegeto E, Shahbaz M M, Wen D X, Goldman M E, O'Malley B W, McDonnell D P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function.  Mol Endocrinol. 1993;  7(10) 1244-1255
    CrossrefPubMedGoogle Scholar
  • 17 Wagner B L, Norris J D, Knotts T A, Weigel N L, McDonnell D P. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.  Mol Cell Biol. 1998;  18(3) 1369-1378
    PubMedGoogle Scholar
  • 18 Mangal R K, Wiehle R D, Poindexter III A N, Weigel N L. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle.  J Steroid Biochem Mol Biol. 1997;  63(4-6) 195-202
    CrossrefPubMedGoogle Scholar
  • 19 Garcia E, Bouchard P, De Brux J et al.. Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating.  J Clin Endocrinol Metab. 1988;  67(1) 80-87
    CrossrefPubMedGoogle Scholar
  • 20 Mylonas I, Jeschke U, Shabani N et al.. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium.  Histol Histopathol. 2007;  22(2) 169-176
    PubMedGoogle Scholar
  • 21 Snijders M P, de Goeij A F, Debets-Te Baerts M J, Rousch M J, Koudstaal J, Bosman F T. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause.  J Reprod Fertil. 1992;  94(2) 363-371
    PubMedGoogle Scholar
  • 22 American Cancer Society .Cancer facts and figures. Atlanta, GA; American Cancer Society 2008
    PubMedGoogle Scholar
  • 23 Creasman W T. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment.  Semin Oncol. 1997;  24(1, Suppl 1) 140-150
    PubMedGoogle Scholar
  • 24 Münstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg H R. Cancer of the endometrium: current aspects of diagnostics and treatment.  World J Surg Oncol. 2004;  2 24
    CrossrefPubMedGoogle Scholar
  • 25 Sherman M E. Theories of endometrial carcinogenesis: a multidisciplinary approach.  Mod Pathol. 2000;  13(3) 295-308
    CrossrefPubMedGoogle Scholar
  • 26 Gallup D G, Stock R J. Adenocarcinoma of the endometrium in women 40 years of age or younger.  Obstet Gynecol. 1984;  64(3) 417-420
    PubMedGoogle Scholar
  • 27 Trimble C L, Kauderer J, Zaino R et al.. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.  Cancer. 2006;  106(4) 812-819
    CrossrefPubMedGoogle Scholar
  • 28 Reifenstein Jr E C. The treatment of advanced endometrial cancer with hydroxyprogesterone caproate.  Gynecol Oncol. 1974;  2(2-3) 377-414
    CrossrefPubMedGoogle Scholar
  • 29 Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis.  Cancer. 1998;  83(1) 111-121
    CrossrefPubMedGoogle Scholar
  • 30 Affinito P, Di Carlo C, Di Mauro P, Napolitano V, Nappi C. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone.  Maturitas. 1994;  20(2-3) 191-198
    CrossrefPubMedGoogle Scholar
  • 31 Clark T J, Neelakantan D, Gupta J K. The management of endometrial hyperplasia: an evaluation of current practice.  Eur J Obstet Gynecol Reprod Biol. 2006;  125(2) 259-264
    CrossrefPubMedGoogle Scholar
  • 32 Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia.  Am J Obstet Gynecol. 1989;  160(1) 126-131
    PubMedGoogle Scholar
  • 33 Gal D, Edman C D, Vellios F, Forney J P. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia.  Am J Obstet Gynecol. 1983;  146(3) 316-322
    PubMedGoogle Scholar
  • 34 Varma R, Soneja H, Bhatia K et al.. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study.  Eur J Obstet Gynecol Reprod Biol. 2008;  139(2) 169-175
    CrossrefPubMedGoogle Scholar
  • 35 Randall T C, Kurman R J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.  Obstet Gynecol. 1997;  90(3) 434-440
    CrossrefPubMedGoogle Scholar
  • 36 Wheeler D T, Bristow R E, Kurman R J. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.  Am J Surg Pathol. 2007;  31(7) 988-998
    CrossrefPubMedGoogle Scholar
  • 37 Ushijima K, Yahata H, Yoshikawa H et al.. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.  J Clin Oncol. 2007;  25(19) 2798-2803
    CrossrefPubMedGoogle Scholar
  • 38 Ramirez P T, Frumovitz M, Bodurka D C, Sun C C, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.  Gynecol Oncol. 2004;  95(1) 133-138
    CrossrefPubMedGoogle Scholar
  • 39 Chiva L, Lapuente F, González-Cortijo L et al.. Sparing fertility in young patients with endometrial cancer.  Gynecol Oncol. 2008;  111(2, Suppl) S101-S104
    CrossrefPubMedGoogle Scholar
  • 40 Kim Y B, Holschneider C H, Ghosh K, Nieberg R K, Montz F J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature.  Cancer. 1997;  79(2) 320-327
    CrossrefPubMedGoogle Scholar
  • 41 Montz F J, Bristow R E, Bovicelli A, Tomacruz R, Kurman R J. Intrauterine progesterone treatment of early endometrial cancer.  Am J Obstet Gynecol. 2002;  186(4) 651-657
    CrossrefPubMedGoogle Scholar
  • 42 Dhar K K, NeedhiRajan T, Koslowski M, Woolas R P. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.  Gynecol Oncol. 2005;  97(3) 924-927
    CrossrefPubMedGoogle Scholar
  • 43 Jones K, Georgiou M, Hyatt D, Spencer T, Thomas H. Endometrial adenocarcinoma following the insertion of a Mirena IUCD.  Gynecol Oncol. 2002;  87(2) 216-218
    CrossrefPubMedGoogle Scholar
  • 44 Kresowik J, Ryan G L, Van Voorhis B J. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.  Obstet Gynecol. 2008;  111(2 Pt 2) 547-549
    CrossrefPubMedGoogle Scholar
  • 45 Kelley R M, Baker W H. Progestational agents in the treatment of carcinoma of the endometrium.  N Engl J Med. 1961;  264 216-222
    CrossrefPubMedGoogle Scholar
  • 46 Piver M S, Barlow J J, Lurain J R, Blumenson L E. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma.  Cancer. 1980;  45(2) 268-272
    CrossrefPubMedGoogle Scholar
  • 47 Decruze S B, Green J A. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review.  Int J Gynecol Cancer. 2007;  17(5) 964-978
    CrossrefPubMedGoogle Scholar
  • 48 Thigpen J T, Brady M F, Alvarez R D et al.. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.  J Clin Oncol. 1999;  17(6) 1736-1744
    PubMedGoogle Scholar
  • 49 Markman M. Hormonal therapy of endometrial cancer.  Eur J Cancer. 2005;  41(5) 673-675
    CrossrefPubMedGoogle Scholar
  • 50 Quinn M A, Cauchi M, Fortune D. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate.  Gynecol Oncol. 1985;  21(3) 314-319
    CrossrefPubMedGoogle Scholar
  • 51 Ehrlich C E, Young P C, Stehman F B, Sutton G P, Alford W M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium.  Am J Obstet Gynecol. 1988;  158(4) 796-807
    PubMedGoogle Scholar
  • 52 Leslie K K, Stein M P, Kumar N S et al.. Progesterone receptor isoform identification and subcellular localization in endometrial cancer.  Gynecol Oncol. 2005;  96(1) 32-41
    CrossrefPubMedGoogle Scholar
  • 53 Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors.  Tumour Biol. 1995;  16(4) 254-260
    CrossrefPubMedGoogle Scholar
  • 54 Arnett-Mansfield R L, deFazio A, Wain G V et al.. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.  Cancer Res. 2001;  61(11) 4576-4582
    PubMedGoogle Scholar
  • 55 Kumar N S, Richer J, Owen G, Litman E, Horwitz K B, Leslie K K. Selective down-regulation of progesterone re+Although+ceptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action.  Cancer Res. 1998;  58(9) 1860-1865
    PubMedGoogle Scholar
  • 56 Jongen V, Briët J, de Jong R et al.. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.  Gynecol Oncol. 2009;  112(3) 537-542
    CrossrefPubMedGoogle Scholar
  • 57 Zheng W, Baker H E, Mutter G L. Involution of PTEN-null endometrial glands with progestin therapy.  Gynecol Oncol. 2004;  92(3) 1008-1013
    CrossrefPubMedGoogle Scholar
  • 58 Mutter G L, Lin M C, Fitzgerald J T et al.. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.  J Natl Cancer Inst. 2000;  92(11) 924-930
    CrossrefPubMedGoogle Scholar
  • 59 Francis L W, Lewis P D, Gonzalez D et al.. Progesterone induces nano-scale molecular modifications on endometrial epithelial cell surfaces.  Biol Cell. 2009;  101(8) 481-491
    CrossrefPubMedGoogle Scholar
  • 60 Dai D, Wolf D M, Litman E S, White M J, Leslie K K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors.  Cancer Res. 2002;  62(3) 881-886
    PubMedGoogle Scholar
  • 61 Ueda M, Fujii H, Yoshizawa K, Abe F, Ueki M. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro.  Jpn J Cancer Res. 1996;  87(5) 524-533
    PubMedGoogle Scholar
  • 62 Smid-Koopman E, Blok L J, Kühne L C et al.. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines.  J Soc Gynecol Investig. 2003;  10(1) 49-57
    CrossrefPubMedGoogle Scholar
  • 63 Hanekamp E E, Kühne L M, Grootegoed J A, Burger C W, Blok L J. Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice.  Endocr Relat Cancer. 2004;  11(4) 831-841
    CrossrefPubMedGoogle Scholar
  • 64 Saito T, Mizumoto H, Tanaka R et al.. Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells.  Cancer Lett. 2004;  209(2) 237-243
    CrossrefPubMedGoogle Scholar
  • 65 Di Nezza L A, Jobling T, Salamonsen L A. Progestin suppresses matrix metalloproteinase production in endometrial cancer.  Gynecol Oncol. 2003;  89(2) 325-333
    CrossrefPubMedGoogle Scholar
  • 66 Jaffe R C, Ferguson-Gottschall S D, Gao W, Beam C, Fazleabas A T. Histone deacetylase inhibition and progesterone act synergistically to stimulate baboon glycodelin gene expression.  J Mol Endocrinol. 2007;  38(3) 401-407
    CrossrefPubMedGoogle Scholar
  • 67 Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.  Endocrinology. 2005;  146(12) 5365-5373
    CrossrefPubMedGoogle Scholar
  • 68 Uchida H, Maruyama T, Ono M et al.. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.  Endocrinology. 2007;  148(2) 896-902
    CrossrefPubMedGoogle Scholar
  • 69 Ohta K, Maruyama T, Uchida H et al.. Glycodelin blocks progression to S phase and inhibits cell growth: a possible progesterone-induced regulator for endometrial epithelial cell growth.  Mol Hum Reprod. 2008;  14(1) 17-22
    CrossrefPubMedGoogle Scholar
  • 70 Dai D, Kumar N S, Wolf D M, Leslie K K. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.  Am J Obstet Gynecol. 2001;  184(5) 790-797
    CrossrefPubMedGoogle Scholar
  • 71 Ward E C, Hoekstra A V, Blok L J et al.. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma.  Endocrinology. 2008;  149(4) 1942-1950
    CrossrefPubMedGoogle Scholar
  • 72 Goto T, Takano M, Albergaria A et al.. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells.  Oncogene. 2008;  27(1) 9-19
    CrossrefPubMedGoogle Scholar
  • 73 Shiozawa T, Nikaido T, Nakayama K, Lu X, Fujii S. Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone.  Mol Hum Reprod. 1998;  4(9) 899-905
    CrossrefPubMedGoogle Scholar
  • 74 Watanabe J, Watanabe K, Jobo T et al.. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.  Int J Gynecol Cancer. 2006;  16(Suppl 1) 452-457
    PubMedGoogle Scholar
  • 75 Vereide A B, Kaino T, Sager G, Ørbo A. Scottish Gynaecological Clinical Trials Group . Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.  Gynecol Oncol. 2005;  97(3) 740-750
    CrossrefPubMedGoogle Scholar
  • 76 Paulssen R H, Moe B, Grønaas H, Orbo A. Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone.  Steroids. 2008;  73(1) 116-128
    CrossrefPubMedGoogle Scholar
  • 77 Hanekamp E E, Kühne E C, Smid-Koopman E et al.. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer.  Eur J Cancer. 2002;  38(Suppl 6) S71-S72
    PubMedGoogle Scholar
  • 78 Davies S, Dai D, Wolf D M, Leslie K K. Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells.  J Soc Gynecol Investig. 2004;  11(7) 494-499
    CrossrefPubMedGoogle Scholar
  • 79 Dai D, Litman E S, Schonteich E, Leslie K K. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth.  J Steroid Biochem Mol Biol. 2003;  87(2-3) 123-131
    CrossrefPubMedGoogle Scholar
  • 80 Davies S, Dai D, Feldman I, Pickett G, Leslie K K. Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2.  Gynecol Oncol. 2004;  94(2) 463-470
    CrossrefPubMedGoogle Scholar
  • 81 Salih S M, Salama S A, Jamaluddin M et al.. Progesterone-mediated regulation of catechol-O-methyl transferase expression in endometrial cancer cells.  Reprod Sci. 2008;  15(2) 210-220
    CrossrefPubMedGoogle Scholar
  • 82 Tamura M, Sebastian S, Yang S et al.. Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B.  J Biol Chem. 2002;  277(29) 26208-26216
    CrossrefPubMedGoogle Scholar
  • 83 Yang S, Fang Z, Gurates B et al.. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2.  Mol Endocrinol. 2001;  15(12) 2093-2105
    CrossrefPubMedGoogle Scholar
  • 84 Lee K, Jeong J, Tsai M J et al.. Molecular mechanisms involved in progesterone receptor regulation of uterine function.  J Steroid Biochem Mol Biol. 2006;  102(1) 41-50
    CrossrefPubMedGoogle Scholar
  • 85 Samalecos A, Gellersen B. Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR)-C, PR-M, or other truncated PR isoforms.  Endocrinology. 2008;  149(11) 5872-5887
    CrossrefPubMedGoogle Scholar

J. Julie KimPh.D. 

Assistant Professor, Division of Reproductive Biology Research, Department Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center

Northwestern University, 303 E. Superior Street, 4-117, Chicago, IL 60611

Email: j-kim4@northwestern.edu

      >